Crewe Advisors LLC Has $351,000 Position in Pfizer Inc. (NYSE:PFE)

Crewe Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 8.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 13,217 shares of the biopharmaceutical company’s stock after selling 1,253 shares during the quarter. Crewe Advisors LLC’s holdings in Pfizer were worth $351,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in PFE. Czech National Bank boosted its stake in Pfizer by 6.9% in the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after purchasing an additional 74,737 shares during the period. Atomi Financial Group Inc. increased its stake in shares of Pfizer by 12.1% in the 3rd quarter. Atomi Financial Group Inc. now owns 42,433 shares of the biopharmaceutical company’s stock valued at $1,228,000 after purchasing an additional 4,583 shares during the last quarter. Country Trust Bank lifted its stake in Pfizer by 46.9% in the 3rd quarter. Country Trust Bank now owns 4,700 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 1,500 shares during the last quarter. Artemis Investment Management LLP boosted its stake in shares of Pfizer by 27.9% during the third quarter. Artemis Investment Management LLP now owns 460,127 shares of the biopharmaceutical company’s stock valued at $13,316,000 after purchasing an additional 100,492 shares in the last quarter. Finally, O Keefe Stevens Advisory Inc. increased its holdings in Pfizer by 24.0% in the third quarter. O Keefe Stevens Advisory Inc. now owns 64,868 shares of the biopharmaceutical company’s stock valued at $1,877,000 after purchasing an additional 12,567 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.46 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $149.94 billion, a price-to-earnings ratio of 35.76, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock has a fifty day simple moving average of $26.27 and a two-hundred day simple moving average of $27.79.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.50%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.